


TD-0212 TFA

Cat. No.:	HY-114412A
CAS No.:	1073549-11-7
Molecular Formula:	C ₃₀ H ₃₅ F ₄ N ₃ O ₆ S
Molecular Weight:	641.67
Target:	Angiotensin Receptor; Neprilysin
Pathway:	GPCR/G Protein; Metabolic Enzyme/Protease
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (194.80 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.5584 mL	7.7922 mL	15.5843 mL
		5 mM		0.3117 mL	1.5584 mL	3.1169 mL
		10 mM		0.1558 mL	0.7792 mL	1.5584 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.24 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.24 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.24 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT ₁) antagonist and neprilysin (NEP) inhibitor, with a pK _i of 8.9 for AT ₁ and a pIC ₅₀ of 9.2 for NEP ^[1] .
IC₅₀ & Target	pK _i : 8.9 (AT ₁) pIC ₅₀ : 9.2 (NEP) ^[1] .
In Vitro	TD-0212 provides the enhanced activity of dual AT ₁ /NEP inhibition with a potentially lower risk of angioedema relative to dual ACE/NEP inhibition ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TD-0212 produces blood pressure reductions similar to omapatrilat and combinations of AT1 receptor antagonists and NEP inhibitors in models of renin-dependent and -independent hypertension^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. McKinnell RM, et al. Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Nephilysin Inhibitor (ARNI). ACS Med Chem Lett. 2018 Dec 3;10(1):86-91.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA